Avilar Therapeutics is a technology company.
Avilar Therapeutics has raised $75.0M across 2 funding rounds.
Avilar Therapeutics has raised $75.0M in total across 2 funding rounds.
Avilar Therapeutics is a biopharmaceutical company developing ATACs (ASGPR Targeting Chimeras), a novel class of extracellular protein degraders that shuttle disease-causing proteins from circulation to the endolysosome for degradation.[1][3][4] Founded in 2019 and based in Waltham, Massachusetts, the company targets high-value indications in women's health, autoimmune/rare neurology, and cardiometabolic disorders with both oral and injectable therapies, addressing proteins outside the cell that traditional degradation methods overlook.[1][2][3] It has raised $75M in funding, presented preclinical data at key summits, and secured U.S. Patent 11,819,551 for broad ATAC protection, signaling strong early momentum in targeted protein degradation.[2]
Avilar Therapeutics was founded in 2019 in Waltham, MA, as a biotech focused on expanding targeted protein degradation beyond intracellular targets to the extracellular proteome.[2][3] While specific founders are not detailed in available sources, the leadership includes a Chief Executive Officer & President, Chief Scientific Officer, and Senior Vice President/Chief Development Officer, driving its platform build.[2] The idea emerged from recognizing that nearly 40% of human proteins are extracellular or membrane-bound and implicated in diseases, yet undruggable by prior intracellular-focused degraders like PROTACs; Avilar pioneered ATACs to harness the liver's natural ASGPR-mediated endolysosomal degradation process.[3][4] Early traction includes a $75M funding round, preclinical pipeline advancements (e.g., IgG degraders for autoimmune diseases and AVL-181 for hepatitis C), patent issuance in 2023, and data presentations at the Targeted Protein Degradation Summit.[2][5]
Avilar rides the targeted protein degradation wave, shifting from intracellular PROTACs to extracellular targets, unlocking ~40% more of the proteome for diseases like autoimmune disorders and cardiometabolic conditions where secretion or circulation hinders traditional inhibition.[3][4] Timing aligns with surging investor interest—evidenced by $75M funding—and advances in endogenous degradation machinery, amid a biotech boom in precision modalities post-2020.[2] Market forces favoring Avilar include rising demand for first-in-class therapies in immunology and metabolism, plus patent protections amid competition from intracellular-focused players. It influences the ecosystem by validating extracellular degradation, potentially inspiring platform expansions and partnerships in the $100B+ protein degradation market.[2][3]
Avilar's ATAC platform positions it for pipeline milestones, including advancing preclinical assets like IgG degraders and AVL-181 into IND-enabling studies or Phase 1 trials, with oral formulations accelerating adoption.[1][5] Trends like AI-driven protein design and combo therapies with PROTACs will shape its path, amplifying extracellular focus amid ~3,000+ undruggable targets. Influence may evolve through big pharma deals or IPO as data readouts validate efficacy in hard-to-treat areas, cementing Avilar as a degradation pioneer—transforming a biotech boundary into standard care.[2][4]
Avilar Therapeutics has raised $75.0M in total across 2 funding rounds.
Avilar Therapeutics's investors include Polaris Partners, Collide Capital, Gutter Capital, Listen, Sheila Lirio Marcelo, Turing Capital, Charles Huang.
Avilar Therapeutics has raised $75.0M across 2 funding rounds. Most recently, it raised $15.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $15.0M Seed | Polaris Partners | |
| Nov 1, 2021 | $60.0M Seed | Collide Capital, Gutter Capital, Listen, Sheila Lirio Marcelo, Turing Capital, Charles Huang |